528 related articles for article (PubMed ID: 7695230)
1. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.
Murray AM; Weihmueller FB; Marshall JF; Hurtig HI; Gottleib GL; Joyce JN
Ann Neurol; 1995 Mar; 37(3):300-12. PubMed ID: 7695230
[TBL] [Abstract][Full Text] [Related]
2. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease.
Joyce JN; Smutzer G; Whitty CJ; Myers A; Bannon MJ
Mov Disord; 1997 Nov; 12(6):885-97. PubMed ID: 9399211
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical study of the striatal efferents and nigral dopaminergic neurons in parkinsonism-dementia complex on Guam in comparison with those in Parkinson's and Alzheimer's diseases.
Goto S; Hirano A; Matsumoto S
Ann Neurol; 1990 May; 27(5):520-7. PubMed ID: 1694418
[TBL] [Abstract][Full Text] [Related]
4. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
[TBL] [Abstract][Full Text] [Related]
5. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease.
Ryoo HL; Pierrotti D; Joyce JN
Mov Disord; 1998 Sep; 13(5):788-97. PubMed ID: 9756147
[TBL] [Abstract][Full Text] [Related]
6. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
Huot P; Lévesque M; Parent A
Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
[TBL] [Abstract][Full Text] [Related]
7. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease.
McRitchie DA; Cartwright HR; Halliday GM
Exp Neurol; 1997 Mar; 144(1):202-13. PubMed ID: 9126172
[TBL] [Abstract][Full Text] [Related]
8. Loss of dopamine D2 receptors in Alzheimer's disease with parkinsonism but not Parkinson's or Alzheimer's disease.
Joyce JN; Murray AM; Hurtig HI; Gottlieb GL; Trojanowski JQ
Neuropsychopharmacology; 1998 Dec; 19(6):472-80. PubMed ID: 9803423
[TBL] [Abstract][Full Text] [Related]
9. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum.
Kaufman MJ; Madras BK
Synapse; 1991 Sep; 9(1):43-9. PubMed ID: 1796351
[TBL] [Abstract][Full Text] [Related]
10. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
Jellinger KA
Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
[TBL] [Abstract][Full Text] [Related]
11. Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization.
German DC; Manaye K; Smith WK; Woodward DJ; Saper CB
Ann Neurol; 1989 Oct; 26(4):507-14. PubMed ID: 2817827
[TBL] [Abstract][Full Text] [Related]
12. The distribution of amyloid beta protein deposition in the corpus striatum of patients with Alzheimer's disease.
Brilliant MJ; Elble RJ; Ghobrial M; Struble RG
Neuropathol Appl Neurobiol; 1997 Aug; 23(4):322-5. PubMed ID: 9292871
[TBL] [Abstract][Full Text] [Related]
13. Loss of striatal histamine H2 receptors in Huntington's chorea but not in Parkinson's disease: comparison with animal models.
Martínez-Mir MI; Pollard H; Moreau J; Traiffort E; Ruat M; Schwartz JC; Palacios JM
Synapse; 1993 Nov; 15(3):209-20. PubMed ID: 7904088
[TBL] [Abstract][Full Text] [Related]
14. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.
Kish SJ; Tong J; Hornykiewicz O; Rajput A; Chang LJ; Guttman M; Furukawa Y
Brain; 2008 Jan; 131(Pt 1):120-31. PubMed ID: 17956909
[TBL] [Abstract][Full Text] [Related]
15. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons.
Uhl GR; Walther D; Mash D; Faucheux B; Javoy-Agid F
Ann Neurol; 1994 Apr; 35(4):494-8. PubMed ID: 8154880
[TBL] [Abstract][Full Text] [Related]
16. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
17. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
Gnanalingham KK; Smith LA; Hunter AJ; Jenner P; Marsden CD
Synapse; 1993 Jun; 14(2):184-94. PubMed ID: 8332947
[TBL] [Abstract][Full Text] [Related]
18. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
[TBL] [Abstract][Full Text] [Related]
19. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
Chu Y; Kordower JH
Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
[TBL] [Abstract][Full Text] [Related]
20. Distribution of catecholamine uptake sites in human brain as determined by quantitative [3H] mazindol autoradiography.
Donnan GA; Kaczmarczyk SJ; Paxinos G; Chilco PJ; Kalnins RM; Woodhouse DG; Mendelsohn FA
J Comp Neurol; 1991 Feb; 304(3):419-34. PubMed ID: 2022757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
